RATIONALE: Although there have been numerous studies on the development of allergen-induced inflammation, the mechanisms leading to resolution of inflammation remain poorly understood. This represents an important consideration because failure to resolve allergen driven inflammation potentially leads to irreversible airway remodeling, characteristic of chronic asthma. OBJECTIVES: We investigated the resolution of allergic inflammation and identified the factors responsible. METHODS: BALB/c and C57BL/6 mice were sensitized to ovalbumin and challenged through the airways to induce allergic inflammation. Mice were analyzed at 24 hours and 7 days after the final challenge. MEASUREMENTS AND MAIN RESULTS: Airway hyperreactivity (AHR) and increased mucus production were present 7 days after the cessation of allergen challenge in BALB/c mice. Persisting AHR correlated with the continued presence of Th2 cells but not eosinophils in the lungs. The role of Th2 cells in maintaining AHR was confirmed using blocking antibodies against T1/ST2, IL-4, and IL-13 during the resolution period. Moreover, AHR in the "Th1 type" C57BL/6 mouse strain was resolved 1 week after allergen challenge, concomitant with clearance of Th2 cells from the lung. Expression of the T1/ST2 ligand, IL-33, also correlated with maintenance of AHR. CONCLUSIONS: We have used blockade of Th2 function and strain differences to show for the first time that resolution of allergic inflammation and AHR may be dependent on the T1/ST2-IL-33 pathway and the presence of Th2 cells, suggesting they are necessary not only for the development of an allergic response but also for its maintenance.
RATIONALE: Although there have been numerous studies on the development of allergen-induced inflammation, the mechanisms leading to resolution of inflammation remain poorly understood. This represents an important consideration because failure to resolve allergen driven inflammation potentially leads to irreversible airway remodeling, characteristic of chronic asthma. OBJECTIVES: We investigated the resolution of allergic inflammation and identified the factors responsible. METHODS: BALB/c and C57BL/6 mice were sensitized to ovalbumin and challenged through the airways to induce allergic inflammation. Mice were analyzed at 24 hours and 7 days after the final challenge. MEASUREMENTS AND MAIN RESULTS: Airway hyperreactivity (AHR) and increased mucus production were present 7 days after the cessation of allergen challenge in BALB/c mice. Persisting AHR correlated with the continued presence of Th2 cells but not eosinophils in the lungs. The role of Th2 cells in maintaining AHR was confirmed using blocking antibodies against T1/ST2, IL-4, and IL-13 during the resolution period. Moreover, AHR in the "Th1 type" C57BL/6 mouse strain was resolved 1 week after allergen challenge, concomitant with clearance of Th2 cells from the lung. Expression of the T1/ST2 ligand, IL-33, also correlated with maintenance of AHR. CONCLUSIONS: We have used blockade of Th2 function and strain differences to show for the first time that resolution of allergic inflammation and AHR may be dependent on the T1/ST2-IL-33 pathway and the presence of Th2 cells, suggesting they are necessary not only for the development of an allergic response but also for its maintenance.
Authors: Jessica S Siegle; Nicole Hansbro; Cristan Herbert; Ming Yang; Paul S Foster; Rakesh K Kumar Journal: Am J Respir Cell Mol Biol Date: 2006-06-22 Impact factor: 6.914
Authors: Tatjana Pecaric-Petkovic; Svetlana A Didichenko; Sacha Kaempfer; Nicole Spiegl; Clemens A Dahinden Journal: Blood Date: 2008-10-27 Impact factor: 22.113
Authors: Molly D Smithgall; Michael R Comeau; Bo-Rin Park Yoon; Dawn Kaufman; Richard Armitage; Dirk E Smith Journal: Int Immunol Date: 2008-06-11 Impact factor: 4.823
Authors: C M Lloyd; T Delaney; T Nguyen; J Tian; C Martinez-A; A J Coyle; J C Gutierrez-Ramos Journal: J Exp Med Date: 2000-01-17 Impact factor: 14.307
Authors: Victor S Ndaw; Daniel Abebayehu; Andrew J Spence; Patrick A Paez; E Motunrayo Kolawole; Marcela T Taruselli; Heather L Caslin; Alena P Chumanevich; Anuya Paranjape; Bianca Baker; Brian O Barnstein; Tamara T Haque; Kasalina N Kiwanuka; Carole A Oskeritzian; John J Ryan Journal: J Immunol Date: 2017-06-21 Impact factor: 5.422
Authors: Martijn C Nawijn; Benoit J A Piavaux; Prescilla V Jeurink; Renée Gras; Marjan A Reinders; Timothy Stearns; Simon Foote; Machteld N Hylkema; Peter C Groot; Ron Korstanje; Antoon J M Van Oosterhout Journal: Am J Respir Cell Mol Biol Date: 2010-10-22 Impact factor: 6.914
Authors: Zhonghan Yang; Rex Sun; Viktoriya Grinchuk; Joan Antoni Fernández-Blanco; Joan Antoni Fernandez Blanco; Luigi Notari; Jennifer A Bohl; Leon P McLean; Thirumalai R Ramalingam; Thomas A Wynn; Joseph F Urban; Stefanie N Vogel; Terez Shea-Donohue; Aiping Zhao Journal: Am J Physiol Gastrointest Liver Physiol Date: 2012-12-20 Impact factor: 4.052
Authors: Melissa Y Tjota; Jesse W Williams; Tiffany Lu; Bryan S Clay; Tiara Byrd; Cara L Hrusch; Donna C Decker; Claudia Alves de Araujo; Paul J Bryce; Anne I Sperling Journal: J Clin Invest Date: 2013-04-15 Impact factor: 14.808